Biography

Adam Schoen is a partner in Brown Rudnick’s Global Life Sciences Practice Group with an emphasis on intellectual property. With over a decade of experience advising life sciences and medical device funds, companies and academic institutions, Adam helps his clients build, grow, invest in, buy and sell companies of all sizes all over the world. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence, licensing and other agreement work.

Adam has experience developing and implementing patent strategies across the life sciences industry, working with therapeutics, biologics, diagnostics, medical device and digital health companies. He works with a variety of technologies, such as small molecule therapeutics, biologics (including immunotherapeutics), next generation sequencing technologies, microfluidics and droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, neurology, spine), medical imaging technology (IVUS and OCT), mass spectrometry and digital health products. He manages patent portfolios of all sizes and develops strategies to maximize and protect intellectual property rights in both the United States and foreign jurisdictions.

Prior to law school, Adam was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals, Inc.

Representation

IP counsel to multiple east coast venture funds for numerous investment transactions in the gene therapy and small molecule therapeutics space and also IP counsel to certain portfolio companies of those funds.

IP counsel to leading west coast venture fund for numerous investment transactions in the gene therapy and immunotherapy space, and also IP counsel to certain of the fund portfolio companies.

IP counsel to east coast venture fund for numerous investment transactions in the medtech space.

IP counsel to Irish venture fund for numerous investment transactions in the medtech space.

Developing patent portfolio for an emerging company with a small molecule cancer asset in clinical trials.

Developing patent portfolio for an emerging company with a small molecule assert for heart disease in clinical trials and have led company through multiple rounds of diligence with investors.

Representing a US university in continued development of multiple mass spectrometry patent portfolios that presently includes over 200 patents worldwide covering various different mass spectrometry technologies that have been licensed to numerous leading analytical instrument companies as well as other emerging companies.

Represented west coast venture fund in licensing and IP due diligence for joint venture deal with a German small molecule therapeutics company to form a new entity to develop a suite of neurology small molecule assets, with continued IP representation of the new entity.

Developing patent portfolio for medical device product for medical device company for treatment of acute decompensated heart failure and have led the company through multiple investor diligences.

Developing patent portfolio for a personalized cellular immunotherapy for a clinical-stage biotechnology company in which the product is presently in clinical trials and have led the company though multiple investor diligences.

Developing patent portfolio for tools company in the immunotherapeutics space that has driven investment and commercial supply agreement with a leading material science and life science products company.

Developing patent portfolio for Irish medtech company with device for treating nasal disorders that has driven multiple successful rounds of investment.

Developing patent portfolio for emerging British company developing safe and effective drug delivery systems for cell and gene therapeutics and have led the company through multiple investor diligences.

Developing patent portfolio for emerging company for a suite of specialized tools for minimally invasive orthopedic procedures and have led the company through multiple investor diligences.

Developing patent portfolios for numerous additional emerging companies, such as:

  • Therapeutics company with a small molecule asset for certain cancers
  • Israeli medical device company with device for treatment of heart failure
  • Therapeutics company with a small molecule asset for treating neurological disorders
  • Therapeutics company with a biologics asset for treating renal disorders
  • Therapeutics company with a small molecule asset for treating pain disorders
  • Digital health company with diagnostic device and proprietary software platform for assessing male fertility
  • Digital health company with diagnostic methods and proprietary software platform for care management solution for workers’ injury prevention and recovery
  • Therapeutics company with products for delivery of drugs to the gastrointestinal system
  • Therapeutics company with small molecule asset for treating kidney disorders
  • Digital health company with software platform for modeling delivery of compounds to different tissues
  • Digital health company with software platform for assessing wellness and diagnosing psychiatric disorders
  • Therapeutics company with products for treating inflammatory conditions
  • Medical device company developing a product for treating infections
  • Medical device company with proprietary software platform developing a product for assessing and monitoring water quality
  • Medical device company with image guided solutions for minimally-invasive procedures
  • Microfluidics company developing microfluidic based immunoassays
  • Medical device company developing bone grafting products
  • Diagnostics company with methods for assessing neurological conditions
  • Medical device company developing an ultrasound based platform for drug delivery
  • Diagnostics company with OCT based methods for assessing disorders.

Developed patent portfolio for T cell therapy company that was acquired by a neuro-immunology company, with continued IP representation of the company after acquisition.

Core member of team that developed and obtained a patent portfolio of over 150 patents for a microfluidics and genetic diagnostics company that was acquired by a biopharmaceutical company for over $75 million, with continued IP representation of the company after acquisition.

Developed patent portfolio for an ablation catheter company to treat atrial fibrillation that was acquired by an Italian medical device company, with continued IP representation of the company after acquisition.

Core member of multidisciplinary team for cross-border transaction for sale of numerous small molecule assets to a leading pharmaceutical company. The work involved analyzing over 50 patents covering the numerous small molecule assets along with analysis of numerous licenses and litigation settlement agreements. The work also involved negotiating IP aspects of the transaction documents.

Core member of team that developed and obtained a patent portfolio of over 100 patents for a next generation sequencing company that were sold to a leading sequencing company.

Core member of team that developed and obtained a patent portfolio of over 30 patents for a fluidics and molecular diagnostic company that was sold to large molecular diagnostic company.

Core member of team that developed patent portfolio for a laparoscopic surgical instrument for a medical device company that was sold to a global leader in medical technology.

Core member of team that developed and obtained a patent portfolio of over 30 patents for a microfluidics company that was acquired by a biopharmaceutical company.

Developed patent portfolio for US university in the microfluidics space that was licensed to a diagnostics company.

IP counsel to large imaging guided therapy company and developed multiple patent portfolios in the ultrasound and OCT space.

IP counsel to large healthcare company and developed multiple patent portfolios in the medical records space and the imaging device space.

Represented US university in the genetic diagnostics space and developed patent portfolio that was licensed to an emerging diagnostics and therapeutics company.

Core member of team that developed patent portfolio for medical device company with product in glaucoma space.

Developed patent portfolio for digital health company with diagnostic device and proprietary software platform for analyzing blood and diagnosing a disorder.

Core member of team that developed patent portfolio for digital health company with diagnostic methods and proprietary software platform for assessing infertility.

Developed patent portfolio for medtech company with a device for treating neurological disorders.

Education

New England School of Law – J.D., magna cum laude, 2006 - New England Scholar - Dean's Honor List
Cornell University – B.S., 1999

Bar Admissions

Massachusetts
Registered Patent Attorney, US Patent and Trademark Office
Publications
Author, "The Impact of Recent Patent Law Cases and Developments" 2016 ed., Chapter: Strategies for Using Patents to Boost a Client's Bottom Line, Aspatore Books, a Thompson Reuters business
Author, "Developing a Patent Strategy," 2015 ed., Aspatore Books, a Thompson Reuters business
Speaking Engagements
Speaker, "How and when to talk to investors and partners about your IP," Rosenman Institute, San Francisco, California (September 2019)
Speaker, "How to build a valuable, unassailable patent portfolio," Rosenman Institute, San Francisco, California (December 2017)
Panelist, "Digital Health panel," The Connected Health Tech-meeting, Boston, Massachusetts (October 2016)
Panelist, "Designing a Unified Patent Prosecution Strategy," The IP Strategy Summit, Boston, Massachusetts (October, 2015)
Speaker, "Effective patent strategy and pitfalls in the pharmaceutical industry," FDA boot-camp, Boston, Massachusetts (2013)
The impact of Prometheus Laboratories v. Mayo Collaborative Services on medical diagnostics
The patentability of genes and isolated DNA in view of Myriad case decisions
The continued Written Description requirement for patents in view of Ariad Pharmaceuticals, Inc. v. Eli Lilly & Company
Food and Drug Administration (FDA) guidance on mobile medical applications